약물난치성 뇌전증 환자의 약물 치료 권고사항: 2021 대한신경과학회 진료지침 뇌전증 분과 소위원회

키워드

참고문헌 (63)

1. Thurman DJ, "Standards for epidemiologic studies and surveillance of epilepsy", Epilepsia, 52(Suppl 7), pp.2~26 (2011)
2. Bertran F, "Epilepsy today", Rev Infirm, 67, pp.14~16 (2018)
3. Löscher W, "Drug resistance in epilepsy:clinical impact, potential mechanisms, and new innovative treatment options", Pharmacol Rev, 72, pp.606~638 (2020)
4. Kim KK, "Clinical guideline for antiepileptic drug treatment in patient with epilepsy", Korean Epilepsy Society, ~ (2015)
5. Kanner AM, "Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society", Neurology, 91, pp.82~90 (2018)
6. Abou-Khalil BW, "Update on antiepileptic drugs 2019", Continuum (Minneap Minn), 25, pp.508~536 (2019)
7. Korean Epilepsy Society Editorial Board, "Clinical Epileptology", pp.353~387 (2018), PANMUNEDU
8. Koeppen D, "Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study", Epilepsia, 28, pp.495~506 (1987)
9. Schmidt D, "Clobazam for refractory focal epilepsy. A controlled trial", Arch Neurol, 43, pp.824~826 (1986)
10. Allen JW, "Clobazam as adjunctive treatment in refractory epilepsy", Br Med J (Clin Res Ed), 286, pp.1246~1247 (1983)
11. French JA, "A double-blind, placebo-controlled study of vigabatrin three g", day in patients with uncontrolled complex partial seizures. Vigabatrin protocol 024 investigative cohort, 1996, pp.46, 54~61
12. Dean C, "Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures", Epilepsia, 40, pp.74~82 (1999)
13. Maguire MJ, "Prevalence of visual field loss following exposure to vigabatrin therapy:a systematic review", Epilepsia, 51, pp.2423~2431 (2010)
14. Manreza MLG, "Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy", Arq Neuropsiquiatr, 79, pp.290~298 (2021)
15. French JA, "Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures", Neurology, 60, pp.1631~1637 (2003)
16. Arroyo S, "Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures", Epilepsia, 45, pp.20~27 (2004)
17. Beydoun A, "Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy", Neurology, 64, pp.475~480 (2005)
18. Elger CE, "Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study", Epilepsia, 46, pp.1926~1936 (2005)
19. French J, "Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes", Neurology, 87, pp.1242~1249 (2016)
20. French J, "Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial", Epilepsia, 55, pp.1220~1228 (2014)
21. Halász P, "Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial", Epilepsia, 50, pp.443~453 (2009)
22. Chung S, "Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial", Epilepsia, 51, pp.958~967 (2010)
23. Ben-Menachem E, "Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures", Epilepsia, 48, pp.1308~1317 (2007)
24. Hong Z, "Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study", Epilepsy Res, 127, pp.267~275 (2016)
25. Krauss G, "Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures", Epilepsia, 51, pp.951~957 (2010)
26. Brodie MJ, "Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial", Epilepsia, 50, pp.1899~1909 (2009)
27. Elger CE, "24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures", Epilepsy Res, 88, pp.255~263 (2010)
28. Biton V, "A randomized, double-blind, placebo controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures", Epilepsia, 52, pp.234~242 (2011)
29. French JA, "Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305", Epilepsia, 54, pp.117~125 (2013)
30. French JA, "Adjunctive perampanel for refractory partial-onset seizures:randomized phase III study 304", Neurology, 79, pp.589~596 (2012)
31. Krauss GL, "Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures", Neurology, 78, pp.1408~1415 (2012)
32. Nishida T, "Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study", Acta Neurol Scand, 137, pp.392~399 (2018)
33. Steinhoff BJ, "Efficacy and safety of adjunctive perampanel 4 mg", d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies, 2020, pp.61, 278~286
34. Chung SS, "Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures", Neurology, 94, pp.e2311~e2322 (2020)
35. Krauss GL, "Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial", Lancet Neurol, 9, pp.38~48 (2020)
36. Sperling MR, "Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study", Epilepsia, 61, pp.1099~1108 (2020)
37. Elger C, "Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double blind, placebo-controlled, parallel-group phase III study", Epilepsia, 50, pp.454~463 (2009)
38. Gil-Nagel A, "Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures", Acta Neurol Scand, 120, pp.281~287 (2009)
39. Ben-Menachem E, "Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy", Epilepsy Res, 89, pp.278~285 (2010)
40. Cramer JA, "Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate", Epilepsy Behav, 53, pp.149~153 (2015)
41. Elger C, "Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: data from four double-blind placebo-controlled pivotal phase III clinical studies", CNS Neurosci Ther, 23, pp.961~972 (2017)
42. Biton V, "Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial", Epilepsia, 55, pp.57~66 (2014)
43. Ryvlin P, "Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial", Epilepsia, 55, pp.47~56 (2014)
44. Klein P, "A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures", Epilepsia, 56, pp.1890~1898 (2015)
45. Ben-Menachem E, "Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies", Neurology, 87, pp.314~323 (2016)
46. Lee SK, "Effect of number of previous antiseizure medications on efficacy and tolerability of adjunctive brivaracetam for uncontrolled focal seizures: post hoc analysis", Adv Ther, 38, pp.4082~4099 (2021)
47. Chung S, "Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a doubleblind, randomised, multicentre, historical control study", Epilepsy Res, 101, pp.92~102 (2012)
48. French J, "Pregabalin monotherapy in patients with partial onset seizures: a historical-controlled trial", Neurology, 82, pp.590~597 (2014)
49. Wechsler RT, "Conversion to lacosamide monotherapy in the treatment of focal epilepsy:results from a historicalcontrolled, multicenter, double-blind study", Epilepsia, 55, pp.1088~1098 (2014)
50. Sperling MR, "Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America", Epilepsia, 6, pp.546~555 (2015)
51. Jacobson MP, "Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study", BMC Neurol, 15, pp.46~ (2015)
52. French J, "Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society", Neurology, 52, pp.1540~1545 (1999)
53. French JA, "Efficacy and tolerability of the new antiepileptic drugs II:treatment of refractory epilepsy", Neurology, 62, pp.1261~1273 (2004)
54. Biton V, "Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic clonic seizures", Neurology, 5, pp.737~1743 (2005)
55. "Guideline projects in process"[URL]
56. Kanner AM, "Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society", Neurology, 91, pp.74~81 (2018)
57. Devinsky O, "Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome", N Engl J Med, 378, pp.1888~1897 (2018)
58. Thiele EA, "Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 391, pp.1085~1096 (2018)
59. Devinsky O, "Trial of cannabidiol for drug-resistant seizures in the dravet syndrome", N Engl J Med, 377, pp.699~700 (2017)
60. Miller I, "Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial", JAMA Neurol, 77, pp.613~621 (2020)
61. Piña-Garza JE, "Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies", Epilepsy Behav, 104(Pt A), pp.106876~ (2020)
62. Kirkham F, "Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial", Epilepsy Behav, 105, pp.106962~ (2020)
63. Farkas V, "Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures", Neurology, 93, pp.e1212~e1226 (2019)

관련 논문AI추천